4 1 5 a r t I C l e S BDNF promotes the neural and behavioral plasticity induced by cocaine or other stimulant drugs of abuse via actions on the mesolimbic dopamine system, which is composed of dopamine neurons in the ventral tegmental area (VTA) of the midbrain and their anterior projections to the nucleus accumbens (NAc) and other forebrain regions [1] [2] [3] . Previous studies have shown that BDNF-TrkB activity and its downstream signaling cascades are induced in NAc by cocaine exposure [4] [5] [6] . In addition, manipulations that enhance BDNF signaling in the VTA-NAc circuit increase rewarding and locomotor responses to cocaine, whereas suppressing BDNF signaling has the opposite effect 5, [7] [8] [9] [10] .
BDNF promotes the neural and behavioral plasticity induced by cocaine or other stimulant drugs of abuse via actions on the mesolimbic dopamine system, which is composed of dopamine neurons in the ventral tegmental area (VTA) of the midbrain and their anterior projections to the nucleus accumbens (NAc) and other forebrain regions [1] [2] [3] . Previous studies have shown that BDNF-TrkB activity and its downstream signaling cascades are induced in NAc by cocaine exposure [4] [5] [6] . In addition, manipulations that enhance BDNF signaling in the VTA-NAc circuit increase rewarding and locomotor responses to cocaine, whereas suppressing BDNF signaling has the opposite effect 5, [7] [8] [9] [10] .
In marked contrast, we recently found that chronic morphine suppresses Bdnf gene expression in mouse VTA and that such a blockade enhances rewarding and locomotor responses to morphine by augmenting dopamine neuron activity 11 . Chronic opiates also induce some unique biochemical and morphological alterations in VTA, such as downregulation of intracellular neurotrophin signaling cascades and reduced soma size of VTA dopamine neurons, which are not seen with stimulants [12] [13] [14] [15] . Notably, some of these changes are reversed by direct administration of BDNF into this brain region.
Despite this evidence for an inverse relationship between BDNF activity in VTA and morphine action, the transcriptional mechanisms underlying Bdnf suppression by morphine are largely unknown.
We carried out a comprehensive analysis of epigenetic regulation at the Bdnf gene and observed a series of interacting chromatin mechanisms that mediate morphine's downregulation of Bdnf transcription in rat VTA. We found that unique binding patterns of RNA polymerase II (Pol II), permissive and repressive histone modifications, their histone-modifying enzymes and related regulatory proteins, and key transcription factors at specific Bdnf promoters were associated with morphine-induced Bdnf suppression in this brain region and with enhanced behavioral responses to opiates.
RESULTS

Downregulation of Bdnf expression in VTA by opiates
We first examined postmortem VTA sections of human brain and observed that heroin addicts, compared with matched controls (Supplementary Table 1 ), displayed reduced mRNA levels of BDNF exon IX, which represents the protein-coding region of BDNF mRNA that is common to all BDNF transcripts 16 ( Fig. 1a and Supplementary Fig. 1a) . Bdnf exon IX mRNA levels were also decreased in VTA of rats that chronically selfadministered heroin ( Fig. 1b and Supplementary Fig. 1b) .
To further characterize VTA Bdnf gene regulation in opiate action, we used an extensively validated morphine treatment regimen, involving repeated intraperitoneal injections, that is more amenable a r t I C l e S to higher throughput analyses. Rats received daily morphine injections (5 mg per kg of body weight) for 14 d and were examined 14 d later 17 . Having confirmed the expected sensitizing behavioral effects of chronic morphine in these rats (Supplementary Fig. 1c) , we found that Bdnf exon IX expression was suppressed in VTA of chronic morphine-treated rats compared with saline controls (one-way ANOVA (F 3,32 = 3.872, P = 0.0181) with Fisher's post hoc test, P = 0.0303; Fig. 1c ). In contrast, acute morphine (5 mg per kg, intraperitoneal) 14 d after chronic (14 d) saline treatment had no effect on Bdnf exon IX expression in rat VTA (Fisher's post hoc test, P > 0.05). However, subchronic morphine exposure (15 mg per kg, intraperitoneal), during 3 d of training for conditioned place preference (CPP), was sufficient to decrease Bdnf exon IX expression in mouse VTA ( Fig. 1d and Supplementary Fig. 1d ). These findings indicate that repeated opiate exposure is required for Bdnf mRNA suppression in VTA across species, including human addicts, and supports the relevance of this adaptation to opiate action.
Stalling of Pol II at Bdnf promoters in VTA by morphine
Having established opiate suppression of Bdnf exon IX expression in VTA, we investigated the underlying mechanisms involved. Initial quantitative PCR (qPCR) analysis revealed that Bdnf transcripts containing exons III, V, VII or VIII were expressed at very low levels in rat VTA and were not altered after chronic morphine ( Supplementary  Fig. 1e ). Thus, we focused on Bdnf transcripts containing exons I, II, IV or VI in VTA and observed that chronic morphine also reduced Bdnf transcript levels of exons II, IV and VI compared with saline controls (Fig. 2a,b) . There was no difference in Bdnf exon I mRNA expression. These data indicate that the chronic morphine-induced suppression of Bdnf exon IX is attributable to reductions in exon II-, exon IV-and exon VI-containing transcripts. Furthermore, our results demonstrate that such suppression is long-lasting: it persisted for at least 2 weeks after cessation of morphine exposure, which is suggestive of an epigenetic mechanism.
To understand the effect of chronic morphine on Bdnf gene transcription at the epigenetic level, we performed quantitative chromatin immunoprecipitation (qChIP) with an antibody that recognizes both non-phosphorylated and phosphorylated forms of Pol II (total Pol II) and with antibodies that specifically recognize Pol II phosphorylated at Figure 1 Opiate-induced downregulation of Bdnf expression in human, rat and mouse VTA. (a) qPCR revealed that mRNA levels of BDNF exon IX were reduced in VTA of human heroin addicts compared with control subjects (unpaired Student's t test, t 12 = 2.623, P = 0.0223, n = 5, 9 human samples). (b,c) mRNA levels of Bdnf exon IX were decreased in VTA of heroin self-administering rats (b, t test, t 22 = 2.793, P = 0.0106, n = 10, 14 rats), and in VTA of rats given 14 daily morphine injections (5 mg per kg, intraperitoneal) and examined after 14 d of withdrawal (c, t test, t 16 = 2.923, P = 0.00995, n = 9 rats), compared with respective control groups. (d) Morphine CPP (15 mg per kg, intraperitoneal) also decreased mRNA levels of Bdnf exon IX in mouse VTA compared with saline-treated mice (t test, t 22 = 2.155, P = 0.0423, n = 12 mice). Unpaired t tests, *P < 0.05 and **P < 0.01. Box plots present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value. Primer information is provided in Supplementary Table 2 . 18 . Total Pol II binding to Bdnf promoter region 2 (Bdnf-p2), which corresponds to exon II, was higher in VTA of chronic morphine-treated rats relative to saline controls, with no changes seen at the other promoters (Fig. 2c) . Phospho-Ser5-Pol II binding to Bdnf-p2, Bdnf-p4 and Bdnf-p6 in morphine-treated rats was increased (Fig. 2d) . In contrast, phospho-Ser2-Pol II binding in coding regions was decreased at Bdnf-exon II (eII), Bdnf-eIV and Bdnf-eVI after chronic morphine (Fig. 2e) . These findings suggest sustained suppression of Bdnf-p2, Bdnf-p4 and Bdnf-p6 via Pol II stalling in VTA in response to chronic morphine.
Histone modifications at Bdnf promoters in VTA by morphine Next, we conducted qChIP for numerous histone modifications at the four Bdnf promoters: three histone markers of gene activation, acetylated H3 (acH3), acH4 and trimethylation of Lys4 of H3 (H3K4me3); three markers of gene repression, H3K9me2, H3K9me3 and H3K27me3; and one marker of transcription elongation, H3K36me3. Chronic morphine-exposed animals displayed clear patterns of histone regulation at Bdnf promoters in VTA ( Supplementary Fig. 2a-g ), with the most pronounced regulation occurring, as with Pol II, at Bdnf-p2. The changes observed in morphine-treated rats represent modifications induced by chronic morphine, which persisted despite 2 weeks of abstinence: acH3 was decreased, whereas H3K4me3 and H3K27me3 were increased, at Bdnf-p2 compared with saline controls (Fig. 3a) . No changes in acH3, H3K4me3 or H3K27me3 were seen at Bdnf-p1, Bdnf-p4 and Bdnf-p6 after morphine exposure ( Supplementary Fig. 2a-g ).
In addition, we observed no alterations in H3K9me2, H3K9me3 or H3K36me3 at any of the Bdnf promoters that we studied, whereas elevated acH4 levels at Bdnf-p4 were observed in morphinetreated rats. The results were replicated in three independent experiments. (h) Intra-VTA HSV-EZH2 suppressed the expression of Bdnf exon IX mRNA in mouse VTA compared with HSV-GFP controls (unpaired t test, t 16 = 2.168, P = 0.0456, n = 9 mice). (i) EZH2 overexpression in mouse VTA markedly enhanced morphine reward (t test, t 22 = 4.134, P = 0.000435, n = 12 mice). Two-way ANOVA with Fisher's PLSD post hoc tests, *P < 0.05, **P < 0.01 and ***P < 0.001; t tests, # P < 0.05 and ### P < 0.001. Bar graphs show mean ± s.e.m. Box plots present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value. npg a r t I C l e S
As follow-up, we performed qChIP for key histone-modifying enzymes and related regulatory proteins associated with a given histone mark, such as mSIN3a (mammalian SIN3 transcription regulator family member A), ING2 (inhibitor of growth 2), MLL1 (mixed lineage, leukemia; KMT2A, lysine-specific methyltransferase 2A), G9a (EHMT2, euchromatic histone-lysine N-methyltransferase 2) and Polycomb group proteins. Given that mSIN3a is a core component of a prominent co-repressor complex implicated in numerous systems 19 , we examined the binding of this protein to Bdnf promoters. We found that mSIN3a binding to Bdnf-p1, Bdnf-p2 and Bdnf-p6 was robustly increased in VTA after chronic morphine ( Fig. 3b and Supplementary  Fig. 2h ). We examined the binding of ING2 to Bdnf promoters, based on our paradoxical observation of increased H3K4me3 levels at Bdnf-p2 in VTA of morphine-treated rats. H3K4me3 typically denotes increased gene transcription, but there is evidence that ING2 represses particular genes by binding to H3K4me3 and recruiting the mSIN3a repressive complex 20, 21 . We found that ING2 binding to Bdnf-p1, Bdnf-p2, Bdnf-p4 and Bdnf-p6 was markedly increased in VTA in response to chronic morphine ( Fig. 3b and Supplementary  Fig. 2i ). Such recruitment of ING2 and mSIN3a to Bdnf promoters explains why an increase in H3K4me3 is associated with gene repression. Consistent with our H3K4me3 data, morphine-treated rats showed elevated binding of an H3K4 methyltransferase, MLL1, to Bdnf-p2 and Bdnf-p6 in VTA ( Fig. 3c and Supplementary Fig. 2j ). In contrast, an H3K9 methyltransferase, G9a, exhibited no changes in binding to Bdnf promoters, consistent with the lack of alterations in H3K9me2 levels ( Fig. 3d and Supplementary Fig. 2k ).
H3K27me3-mediated gene repression is associated with Polycomb group proteins, which reside in two main complexes: PRC1 (Polycomb repressive complex 1) and PRC2. PRC2 contains SUZ12 (zinc finger protein suppressor of zeste 12) and EZH2 (enhancer of zeste homolog 2); the latter catalyzes H3K27me3 (refs. 22,23) . PRC1, which contains BMI1, RING1A and RING1B, contributes to histone H2A monoubiquitination and interactions of Polycomb group proteins with H3K27me3 (refs. 24, 25) . Consistent with increased levels of H3K27me3 at Bdnf-p2, the binding of PRC2 complex proteins-namely, SUZ12 and EZH2-to Bdnf-p2 was increased in VTA by chronic morphine (Fig. 3e) . High levels of occupancy by EZH2, but not SUZ12, were also found at Bdnf-p4 and Bdnf-p6 (Supplementary Fig. 2l,m) . In contrast, binding of PRC1 complex proteins, such as RING1A, to Bdnf-p2 was reduced by morphine, whereas no changes were seen at other Bdnf promoters or in RING1B and BMI1 binding at any promoter ( Fig. 3f and Supplementary Fig. 2n-p) . This comprehensive analysis of epigenetic regulation of the Bdnf gene in VTA by chronic morphine reveals concerted modifications predominantly at Bdnf-p2 that are consistent with transcriptional repression (Supplementary Fig. 2q ). Whitney U tests and Student's t tests showed that EZH2 overexpression increased H3K27me3 levels at all Bdnf promoters examined (Bdnf-p1, U test, U = 5, P = 0.013; Bdnf-p2, t test, t 12 = 2.957, P = 0.012; Bdnf-p4, t test, t 12 = 2.781, P = 0.0166; Bdnf-p6, U test, U = 2, P = 0.003). (h) EZH2 overexpression significantly reduced phospho-CREB binding to Bdnf-p1, Bdnf-p2, Bdnf-p4 and Bdnf-p6 (two-way ANOVA, drug effect: F 1,36 = 25.091, P < 0.001; region effect: F 3,36 = 0.182, P = 0.908; drug × region effect: F 3,36 = 0.104, P = 0.957, n = 5,6 rats). Two-way ANOVA with Fisher's PLSD post hoc tests, *P < 0.05, **P < 0.01 and ***P < 0.001 (a,b,g,h); Mann-Whitney U test, **P < 0.01 (d); Student's t test, *P < 0.05 (f); Mann-Whitney U tests at Bdnf-p1 and Bdnf-p6 and Student's t tests at Bdnf-p2 and Bdnf-p4, # P < 0.05 and ## P < 0.01 (g). Bar graphs show mean ± s.e.m. Box plots present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value. npg a r t I C l e S To directly test whether alterations in H3K27me3 in VTA influence Bdnf expression and morphine-elicited behavioral changes, we generated a herpes simplex virus (HSV) vector to overexpress EZH2 selectively in VTA compared with HSV-GFP controls (Fig. 3g and Supplementary Figs. 3a and 4a) . Such EZH2 overexpression, which was selective for VTA and not seen in neighboring brain regions (Supplementary Fig. 4a) , reduced Bdnf mRNA levels in VTA (Fig. 3h) and robustly increased morphine CPP (5 mg per kg) in mice (Fig. 3i) . In contrast, intra-VTA infusion of a lentiviral vector expressing a short hairpin interfering RNA of Ezh2 (LV-shRNA-EZH2), which repressed Ezh2 mRNA expression ( Supplementary  Fig. 3b,c) , blocked the morphine-induced reduction of Bdnf expression in VTA (Supplementary Fig. 3d ).
Regulation of CREB binding to Bdnf promoters by morphine
We next examined CREB, which induces Bdnf in other systems 26 . Total CREB binding to Bdnf-p6 was increased in VTA in chronic morphine-treated rats, with no changes being observed at the other promoters (Fig. 4a) . However, the binding of phospho-CREB (its active form) to Bdnf-p1, Bdnf-p2 and Bdnf-p4 was robustly decreased under these conditions (Fig. 4b) . To confirm the direct connection between CREB activity and Bdnf expression in VTA, we infused HSV-CREB into VTA of wild-type mice to overexpress CREB selectively in this region (Fig. 4c) . CREB overexpression augmented Creb1 mRNA and protein levels selectively in VTA (Supplementary Figs. 4b  and 5a) ; it also increased Bdnf mRNA expression in VTA compared with HSV-tdTomato (TMT) controls (Fig. 4d) . Conversely, knocking down CREB by infusing HSV-Cre into the VTA of mice with loxP-flanked Creb1 mice (Fig. 4e and Supplementary Fig. 5b) decreased Bdnf expression compared with HSV-GFP controls (Fig. 4f) .
Next, we addressed how chronic morphine suppresses phospho-CREB binding selectively to Bdnf, even though chronic morphine increases overall CREB activity in this brain region 27, 28 . We tested the hypothesis that elevated H3K27me3 suppresses phospho-CREB The results were replicated in two independent experiments. (j) HSV-mediated NURR1 overexpression increased the expression of Bdnf exon IX mRNA in rat VTA (unpaired t test with Welch's correction, t 10.98 = 2.440, P = 0.0328, n = 9,10 rats). (k) NURR1 overexpression in mouse VTA significantly decreased morphine reward (15 mg per kg, intraperitoneal) (unpaired t test, t 13 = 2.165, P = 0.0496, n = 8, 7 mice). (l) However, there was no effect of NURR1 overexpression on morphine reward in mice with a local knockout of BDNF in VTA (t test, t 17 = 0.4062, P = 0.690, n = 10,9 mice). (b-e,k,l) Student's t-tests, *P < 0.05; (f,j) Student's t tests with Welch's correction, *P < 0.05 and **P < 0.01. Bar graphs show mean ± s.e.m. Box plots present, in ascending order, minimum sample value, first quartile, median, third quartile and maximum sample value. npg a r t I C l e S binding to Bdnf promoter regions, as a recent study showed that H3K27me3 antagonizes CREB activity and represses expression at certain gene promoters in lymphocytes 29 . EZH2 overexpression by itself (that is, without morphine), which increased H3K27me3 levels at all Bdnf promoters (Fig. 4g) , decreased phospho-CREB binding to all Bdnf promoters (Fig. 4h) . Moreover, in contrast with the morphineinduced decrease in phospho-CREB binding to the Bdnf promoters, phospho-CREB binding was increased by chronic morphine at the promoters of Th (tyrosine hydroxylase) and Gria1 (GluA1 AMPA receptor subunit), two known CREB target genes that are induced in rodent VTA under these conditions 27, 28 ( Supplementary Fig. 6a,b) . H3K27me3 levels at Th and Gria1 were not affected in VTA by chronic morphine (Supplementary Fig. 6c ). In contrast with Bdnf repression by EZH2 overexpression, Th and Gria1 expression was not altered by EZH2 in mouse VTA (Supplementary Fig. 3a) . Heroin selfadministration also decreased phospho-CREB binding to all Bdnf promoters ( Supplementary Fig. 6d,e) and increased H3K27me3 at Bdnf-p1, Bdnf-p2 and Bdnf-p4 (Supplementary Fig. 6f ).
Regulation of NURR1 binding to Bdnf promoters by morphine
We also examined the transcription factor NURR1 (nuclear receptor related 1), as it regulates several genes including Bdnf in midbrain dopamine neurons [30] [31] [32] [33] . NURR1 binding to Bdnf-p1 and Bdnf-p2 was decreased in VTA of chronic morphine-treated rats (Fig. 5a) . Notably, chronic morphine suppressed Nurr1 mRNA expression in VTA, an effect that we also observed in heroin self-administering rats (Fig. 5b,c) , which could explain the reduced NURR1 binding to Bdnf promoters. Consistent with Nurr1 suppression, H3K27me3 binding at the Nurr1 promoter in VTA was increased by chronic morphine (Fig. 5d) . Furthermore, we examined the relationship between CREB and NURR1 in response to chronic morphine, as Nurr1 is a known downstream target of CREB in other systems 32, 34 . Chronic morphine decreased phospho-CREB binding to the Nurr1 promoter in VTA (Fig. 5e) , whereas CREB overexpression in mouse VTA using HSV-CREB, which induced total and phospho-CREB binding to the Nurr1 promoter (Supplementary Fig. 5c,d) , robustly augmented Nurr1 mRNA expression in this region (Fig. 5f) . The induced H3K27me3 and reduced phospho-CREB binding at Nurr1 in VTA in response to chronic morphine suggest an antagonistic relationship between H3K27me3 and phospho-CREB, as also observed for the Bdnf promoter under these conditions. We generated and validated an HSV vector to overexpress NURR1 and examine its functional role selectively in VTA ( Supplementary  Figs. 4c and 7a) . We first infused HSV-NURR1 into rat VTA 10 d after the last injection of our standard 14-d chronic morphine procedure (5 mg per kg, intraperitoneal). Rats were then reexposed to morphine (5 mg per kg, intraperitoneal) 4 d after the HSV-NURR1 infusion (Fig. 5g) ; such reexposure (M/M) induced higher locomotor responses than a saline challenge (M/S) (Supplementary Fig. 1c) . We observed that NURR1 overexpression in VTA blocked this hyper-locomotion by morphine reexposure (Fig. 5h and Supplementary Fig. 7b) . We also investigated the influence of NURR1 on morphine reward using the CPP procedure. We first confirmed that NURR1 overexpression induced Bdnf expression in mouse VTA, as observed in rat (Fig. 5i,j) , and then found that morphine reward was also blocked by NURR1 overexpression in mouse VTA (Fig. 5k) . Notably, NURR1 overexpression in VTA of mice lacking BDNF in this brain region (generated by infusing HSV-Cre into VTA of mice with loxP-flanked Bdnf) did not result in the suppressive effect of NURR1 overexpression on morphine reward (Fig. 5l) , which provides a direct link between NURR1 action and regulation of BDNF activity in this brain region.
DISCUSSION
Consistent with prior reports of opiate regulation of VTA BDNF expression 11, 35 (but see ref. 36 ), we found that Bdnf mRNA levels were robustly reduced in VTA of human heroin addicts, heroin selfadministering rats and repeated morphine-treated mice (including those undergoing CPP). We observed that chronic morphine exposure induces a robust and sustained decrease in levels of specific Bdnf exon transcripts (that is, Bdnf exons II, IV and VI) in this brain region in rats. A uniquely comprehensive analysis of epigenetic mechanisms-particularly for a micronucleus such as VTA-revealed that this Bdnf suppression by chronic morphine is associated with a series of interacting and sustained transcriptional and chromatin modifications at the corresponding Bdnf gene promoters. In particular, we found that chronic morphine decreases binding of the active (phospho-Ser2) form of Pol II within Bdnf-eII, Bdnf-eIV and Bdnf-eVI, whereas phospho-Ser5 Pol II binding to Bdnf-p2, Bdnf-p4 and Bdnf-p6 was augmented in VTA. These findings suggest that chronic morphine induces a sustained Pol II stalling at certain Bdnf promoters in concert with the gene's sustained repression.
Such stalling of Pol II is associated with several other key chromatin changes, with the most robust regulation seen at Bdnf-p2 in VTA (Supplementary Fig. 2q ). Consistent with repression of Bdnf-p2, we found increased binding of H3K27me3, a major form of repressive histone methylation. Occupancy by the PRC2 complex, including SUZ12 and EZH2, which mediates H3K27 trimethylation 22, 23 , at Bdnf-p2 in VTA was also increased by chronic morphine. Our results provide a causal connection between H3K27me3 and suppression of the Bdnf gene in VTA by showing that EZH2 overexpression in this region decreased Bdnf expression, whereas EZH2 knockdown blocked morphine's suppression of Bdnf. Taken together, these data support a scheme in which PRC2-mediated H3K27me3 reduces Bdnf gene expression (Supplementary Fig. 8) . Notably, PRC2 has been shown to interact with other repressor proteins, particularly with mSIN3a and related proteins 37, 38 , which are also enriched at Bdnf-p2 in VTA in response to chronic morphine. Consistent with our previous study, which linked reduced levels of VTA BDNF with increased morphine reward 11 , we found that EZH2 overexpression in VTA promotes this morphine-elicited behavior as well.
Repression of Bdnf-p2 was associated with increased levels of H3K4me3, which is typically related to gene activation. This observation illustrates the complexity of chromatin regulatory mechanisms in vivo. Insight into this complexity is provided by our observation that this paradoxical increase in H3K4me3 was associated with induction of ING2 binding to Bdnf-p2 by morphine. ING2, which is also a subunit of the repressive mSIN3a complex, binds with high specificity to H3K4me3 and consequently represses transcription of certain genes 20, 21 . We found that this unusual, but with precedent, interaction between H3K4me3 and the mSIN3a/ING2 also involved the morphineinduced recruitment of the H3K4-specific methyltransferase MLL1 (ref. 39) to Bdnf-p2 (Supplementary Fig. 8) . Notably, MLL1, similar to its H3K4me3 mark, has been shown to interact with repressive complexes at particular genes in other systems 40 .
The morphine-induced Bdnf repression also involves reduced binding of a key transcription factor, phospho-CREB, which has previously been shown to induce Bdnf gene expression in other systems 26 . However, the reduced phospho-CREB binding to Bdnf promoters in VTA after chronic morphine is surprising, as chronic morphine increases total levels of phospho-CREB and CREB transcriptional activity in VTA 27, 28 . These findings suggest that there are specific features at Bdnf promoters that are responsible for the exclusion of phospho-CREB after chronic morphine. We found that one a r t I C l e S mechanism for this exclusion is the induction of H3K27me3-as EZH2 overexpression, which induces H3K27me3-in VTA in the absence of morphine reduces phospho-CREB binding to Bdnf promoters. A recent study has reported that PRC2 occupancy and increased H3K27me3 at certain gene promoters antagonizes CREB binding to silence gene expression in lymphocytes 29 . In contrast, phospho-CREB binding to the promoters of Th and Gria1, two known targets of phospho-CREB in VTA 28 , were increased in response to chronic morphine, as would be expected. It is notable that chronic morphine did not affect H3K27me3 levels at Th and Gria1 promoters and that Th and Gria1 mRNA expression was not altered by EZH2 overexpression in contrast to Bdnf expression. Although a caveat of these studies is potential off-target effects of overexpressed transcription factors, our findings together suggest that reduced phospho-CREB binding to Bdnf promoters is mediated by the selective recruitment of H3K27me3 to key Bdnf promoters during a course of opiate exposure.
Bdnf gene regulation is also known to be controlled by NURR1, which is required for maintenance of adult dopamine neurons in VTA 33 ; NURR1 acts downstream of CREB 32, 34 and upstream of BDNF 31, 32 . This connection between CREB and NURR1 is supported by our data that Nurr1 mRNA expression was induced in VTA following CREB overexpression. This finding supports the hypothesis that the morphine-induced reduction in phospho-CREB binding to the Nurr1 promoter that we observed mediates the Nurr1 suppression in VTA by chronic morphine. In parallel, we found that Nurr1 mRNA levels and NURR1 binding to Bdnf promoters were decreased in this region by morphine. Our observation that Bdnf mRNA levels were increased in VTA following NURR1 overexpression is consistent with the scheme that reduced NURR1 binding to Bdnf promoters contributes to Bdnf suppression in response to morphine. This scheme is also supported by our behavioral data: chronic morphine-induced locomotor responses, as well as morphine-elicited reward, were blocked by NURR1 overexpression in VTA. Given that NURR1 overexpression induced Bdnf, these behavioral data are consistent with prior reports that elevated VTA BDNF activity is also associated with suppression of morphine's behavioral effects 11 . Such a connection between NURR1 and BDNF was established by our demonstration that NURR1's ability to suppress morphine-elicited behaviors was lost in mice lacking BDNF selectively in this brain region.
In conclusion, our findings reinforce the complexity of gene and chromatin regulation in adult brain and emphasize the importance of examining numerous chromatin endpoints when investigating epigenetic mechanisms of gene regulation in vivo ( Supplementary  Fig. 8 ). Given that morphine's suppression of Bdnf in VTA makes an important contribution to the drug's behavioral effects 11 , our results provide new insight into the detailed molecular mechanisms underlying morphine-induced neural and behavioral plasticity.
METHODS
Methods and any associated references are available in the online version of the paper. rabbit monoclonal, Cell Signaling, 5246S), antibody to total-CREB (1:1,000; rabbit monoclonal, Millipore, 17-600) and antibody to NURR1 were used. Blots were imaged with the Odyssey Infrared Imaging system (Li-Cor) and quantified by densitometry using ImageJ (US National Institutes of Health). The amount of protein blotted onto each lane was normalized to levels of tubulin. Western blot analyses were replicated at least twice. Full-length western blots are presented in Supplementary Figure 10. experiment 1: Bdnf downregulation by opiates. We examined the effect of opiate exposure on Bdnf mRNA expression in human, rat and mouse VTA. Total RNA was isolated from postmortem brain specimens of human heroin addicts (n = 9) and controls (n = 5) (Supplementary Table 1) . VTA punches (bilateral, 14-gauge) were collected from previously frozen brains of rats that were killed 24 h after the final heroin self-administration session (n = 24) ( Supplementary  Fig. 1b) . We also freshly dissected 14-gauge bilateral rat VTA punches 30 min after completing the last locomotor activity test on day 28 ( Supplementary  Fig. 1c) , after 14 d withdrawal from 14 d of prior morphine administration (n = 18). Mouse VTA punches (bilateral, 15 gauge) were freshly dissected 1 h after completing morphine CPP test sessions (n = 24) (Supplementary Fig. 1d ). experiment 2: stalling of Pol II at Bdnf promoters by morphine. For each ChIP sample, VTA punches were pooled from two rats (four punches) that were killed on day 28, after 14 d withdrawal from 14 d of prior morphine administration (n = 20 or 24). Antibody to total-Pol II (mouse monoclonal, Millipore, 05-623), antibody to phospho-Ser2-Pol II (antibody to Pol II phosphorylated at Ser2 of its C-terminal domain) (mouse monoclonal, Abcam, ab24758) or antibody to phospho-Ser5-Pol II (rabbit polyclonal, Abcam, ab5131) was used for this experiment. Primers for qChIP with antibody to total-Pol II and antibody to phospho-Ser5-Pol II were designed to amplify 150-200-bp products that include CREB binding sites of Bdnf promoters. Primers for qChIP with antibody to phospho-Ser2-Pol II were designed to amplify 150-200-bp products in the coding sequence of the Bdnf gene (Supplementary Table 3 ). experiment 3: histone modifications by morphine. For each ChIP sample for histone modifications, VTA punches (two punches) were collected from one control or chronic morphine-treated rat (14 d of morphine administration followed by 14 d of withdrawal) (n = 8-11 for each ChIP). For each ChIP sample for key histone-modifying enzymes and related regulatory proteins, VTA punches were pooled from two rats (4 punches) (n = 14-22). Antibody to acH3 (rabbit polyclonal, Millipore, 06-599), antibody to acH4 (rabbit polyclonal, Millipore, 06-598), antibody to H3K4me3 (rabbit monoclonal, Millipore, 17-614), antibody to H3K9me2 (mouse monoclonal, Abcam, ab1220), antibody to H3K9me3 (rabbit polyclonal, Abcam, ab8898), antibody to H3K27me3 (mouse monoclonal, Abcam, ab6002), antibody to H3K36me3 (rabbit polyclonal, Abcam, ab9050), antibody to mSIN3a (rabbit polyclonal, Santa Cruz, sc-994X), antibody to ING2 (rabbit polyclonal, Santa Cruz, sc-134973), antibody to KMT2A/MLL (rabbit polyclonal, Millipore, ABE240), antibody to KMT1C/G9a (rabbit polyclonal, Abcam, ab40542), antibody to SUZ12 (rabbit monoclonal, Cell Signaling, 3737S), antibody to EZH2, antibody to RING1A (rabbit polyclonal, Abcam, ab32644), antibody to RING1B (rabbit monoclonal, Cell Signaling, 5694S) and antibody to BMI1 (rabbit monoclonal, Cell Signaling, 6964S) were used. experiment 4: role of eZH2 in Bdnf expression and morphine cPP. Stereotaxic surgery was performed on adult male c57BL/6 mice (8 weeks) to inject HSV-EZH2-GFP or HSV-GFP into the VTA. The first batch of mice (n = 18) was killed for qPCR for validation (Supplementary Fig. 3a) and Bdnf expression (Fig. 3h) 4 d after stereotaxic surgery. Viral injection sites were confirmed using standard histological methods (see Fig. 3g ) using VTA sections from a subset of HSV-EZH2 infused mice (n = 3). A second batch of mice (n = 24) was used for morphine CPP (Fig. 3i) . 2 d after the surgery, mice were conditioned in a threechambered CPP box for 3 d. The next day, animals were given a final CPP test.
Separate groups of rats were bilaterally injected with LV-shRNA-EZH2 (iV000225, Applied Biological Materials) or LV-shRNA-scramble (LVP015-G) in VTA. The first batch of rats (n = 22) was killed for qPCR for validation (Supplementary Fig. 3c ) 10 d after stereotaxic surgery. Viral injection sites were confirmed using standard histological methods (Supplementary Fig. 3b ) using VTA sections from a subset of LV-shRNA-EZH2 infused rats (n = 3).
A second batch of rats (n = 14) was used for qPCR for Bdnf expression after chronic morphine treatment (Supplementary Fig. 3d) . Briefly, we first injected morphine (5 mg per kg, intraperitoneal) for 14 d and bilateral viral injections with LVs were performed 4 d after the last morphine injection. Rats were killed and VTA punches (bilateral, 14 gauge) were collected 10 d after surgery. experiment 5: role of cReB in Bdnf expression. For total-and phospho-CREB ChIP experiments, VTA punches were pooled from two chronic morphinetreated rats (14 d of morphine administration followed by 14 d of withdrawal) (n = 16 or 20 for each). Antibody to total CREB and antibody to phospho-CREB (rabbit polyclonal, Millipore, 06-519) were used for immunoprecipitation. In separate groups of animals, we performed stereotaxic surgery on male c57BL/6 mice or floxed CREB mice to inject HSV-CREB or HSV-Cre and their controls (HSV-TMT or HSV-GFP, respectively) into the VTA. The HSV-CREB/HSV-TMT infused c57BL/6 mice (n = 17) and HSV-Cre/HSV-GFP infused floxed CREB mice (n = 20) were killed for qPCR for validation (Supplementary Fig. 5a,b) and Bdnf expression (Fig. 4d,f) 4 d after stereotaxic surgery. Viral injection sites were confirmed using standard histological methods (Fig. 4c,e) using VTA sections from a subset of HSV-CREB or HSV-Cre infused mice (n = 3 each). experiment 6: interaction between pcReB and H3k27me3. Stereotaxic surgery was performed on adult rats to inject HSV-EZH2 or HSV-GFP into the VTA. Two batches of rats were killed for H3K27me3 ChIP (n = 14) and pCREB ChIP (n = 22) at Bdnf promoters (Fig. 4g,h ) 4 d after stereotaxic surgery. For these ChIP experiments, VTA punches were pooled from two rats. For H3K27me3 ChIP experiment, punches from one rat were used. mRNA levels of Bdnf exon IX were also measured using cDNA derived from VTA of HSV-EZH2 or HSV-GFP infused mice (from Experiment 4) (Supplementary Fig. 3a) . ChIP experiments with antibody to phospho-CREB, antibody to total CREB, and antibody to H3K27me3 were also conducted at Bdnf promoter regions with VTA punches from heroin self-administered rats (anti-phospho-CREB, n = 20; antibody to total CREB, n = 14; antibody to H3K27me3, n = 11) ( Supplementary  Fig. 6d-f) .
Another set of ChIP experiments with antibody to phospho-CREB, antibody to total CREB and antibody to H3K27me3 was conducted as a control at Th and Gria1 promoter regions with control and chronic morphine-treated rats (14 d of morphine administration followed by 14 d of withdrawal) (antibody to phospho-CREB, n = 32; antibody to total CREB, n = 18; antibody to H3K27me3, n = 10) (Supplementary Fig. 6a-c ). experiment 7: interaction between nURR1 and cReB. ChIP experiment with antibody to NURR1 was conducted at Bdnf promoters with chronic morphinetreated rats (14 d of morphine administration followed by 14 d of withdrawal) (n = 18). Another set of ChIP experiments with antibody to H3K27me3 and antibody to phospho-CREB was conducted at Nurr1 promoter regions with chronic morphine-treated rats (antibody to H3K27me3, n = 10; antibody to phospho-CREB, n = 36). In separate experiments, stereotaxic surgery was performed on rats to inject HSV-CREB or HSV-TMT into the VTA. Two batches of rats were killed for total (n = 20) and phospho-(n = 20) CREB ChIP at the Nurr1 promoter (Supplementary Fig. 5c,d ). For NURR1 ChIP and total/phospho-CREB ChIP experiments, VTA punches were pooled from two rats. For H3K27me3 ChIP experiment, bilateral punches from one rat were used. Nurr1 mRNA levels in VTA were also measured using cDNA derived from chronic morphine-treated rats from heroin self-administering rats, or from HSV-CREB infused mice generated from prior experiments. experiment 8: behavioral and molecular effects of nURR1. We performed stereotaxic surgery on rats to inject HSV-NURR1 or HSV-TMT into the VTA. The rats (n = 19) were killed for qPCR validation (Supplementary Fig. 7a ) and Bdnf expression (Fig. 5j) 4 d after stereotaxic surgery. Viral injection sites were confirmed using standard histological methods (Fig. 5i) using VTA sections from a subset of HSV-NURR1 infused rats (n = 3). Another set of rats was given daily injection of morphine (5 mg per kg, intraperitoneal; n = 27) or saline (n = 11) for 14 d. Each morphine-/saline-injected batch was then reexposed to morphine (5 mg per kg, intraperitoneal) or saline on day 28. All of these rats underwent locomotor activity tests on day 0, 14 and 28 and stereotaxic surgery with HSV-NURR1 or HSV-TMT into the VTA 10 d after the last injection of npg chronic morphine or saline (on day 24) (Fig. 5g,h and Supplementary Fig. 7b) . In a separate experiment, stereotaxic surgery was performed on adult male c57BL/6 mice (8 weeks) or floxed BDNF mice to inject HSV-NURR1, HSV-TMT, and/or HSV-Cre into the VTA. In case of floxed BDNF mice, we infused 0.25 µl of HSV-NURR1 or HSV-TMT together with 0.25 µl of HSV-Cre. 2 d after the surgery, the HSV-NURR1/HSV-TMT infused c57BL/6 mice (n = 15) and HSV-NURR+HSV-Cre/HSV-TMT+HSV-Cre infused floxed BDNF mice (n = 19) were conditioned in a three-chambered CPP box for 3 d. The next day, animals were given a final CPP test. All experimental designs are summarized in Supplementary Table 5. Statistical analysis. Sample sizes were similar to those reported in previous works and based on expected effect sizes and power analyses 1, 7, 11, 15, 28, 42, 44, 48 . Data were collected and processed randomly and analyzed with SigmaPlot 12.5 (Systat) and Prism 5.0 (GraphPad). Data collection and analysis were not performed blind to the conditions of the experiments. Normality (Shapiro-Wilk test) and equal variance (F test) assumptions were confirmed before parametric analysis, unless otherwise indicated. For normally distributed data, Student's t tests were used to assess differences between two experimental groups. For a two-sample comparison of means with unequal variances, Student's t tests with Welch's correction were used. One-way ANOVAs were used for analysis of three or more groups, followed by Fisher's PLSD post hoc tests. For all qChIP analyses, two-way ANOVAs with Fisher's PLSD post hoc tests were used. For locomotor activity and heroin self-administration data, a repeated-measures two-way ANOVA was used followed by Fisher's PLSD post hoc tests. Main and interaction effects were considered significant at P < 0.05. Mann-Whitney U tests were performed to compare two columns of non-normally distributed data. Outliers were excluded from analysis when identified by Grubbs' test.
A Supplementary methods checklist is available.
